Develops and commercializes a unique technology aimed at detecting early biomarkers in lung medicine. Pexa offer a non-invasive method for sampling biological material from the liquid layer that covers the human's most distal airways, which gives new opportunities for the development of more precise diagnostics and effective drugs.
Impact: Contribute to a better life for patients with respiratory diseases by facilitating the development of faster and more reliable diagnosis, follow-up and treatment.
CEO: Erik Ekbo
GUV Contact: Jan Pilebjer
Impact: Contribute to a better life for patients with respiratory diseases by facilitating the development of faster and more reliable diagnosis, follow-up and treatment.
CEO: Erik Ekbo
GUV Contact: Jan Pilebjer
Location: Sweden, Gothenburg
Investors 1
| Date | Name | Website |
| - | GU Venture... | guventures... |
Mentions in press and media 2
| Date | Title | Description |
| 16.10.2025 | Everdrone strengthens commercial capacity to drive international expansion | Everdrone strengthens commercial capacity to drive international expansion Thu, Oct 16, 2025 08:44 CET Report this content Swedish health-tech company Everdrone has appointed Erik Ekbo as Head of Sales, marking a strategic move to strengthe... |
| 11.04.2023 | Startup Showcase: PExA – A Revolutionary Instrument for Respiratory Disease Research | Respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), affect millions of people worldwide, and can cause significant morbidity and mortality. Research into these diseases has been hampered by the lack of rel... |